OpenEvidence raised $250M at $15B — below the $20B it floated in July
The "ChatGPT for doctors" raised another nine-figure round. The number isn't the story — the way it surfaced is.
OpenEvidence, the AI search engine for physicians, has raised $250 million at a $15 billion valuation — up from $12 billion in January, but below the $20 billion the company was reported to be weighing in July. The round was disclosed in a single sentence buried in a Forbes story about the company's Memorial Sloan Kettering partnership on September 16, then confirmed by Business Insider on September 24, both citing people familiar with the matter. Investors include hospital systems and Andreessen Horowitz, per Business Insider. There was no press release, no blog post, and no interview with chief executive Daniel Nadler — a sharp break from January, when the $250 million Series D at a $12 billion valuation arrived with a wire release and a press tour.
That contrast is the substance here. In July, The Information reported OpenEvidence was weighing a $200 million raise at a $20 billion valuation. Taking more money at a valuation roughly a quarter lower, three months later, is either a pragmatic decision to bank capital while it is available or a sign the market repriced the story — and the company's choice not to talk about it makes the second reading hard to dismiss. Digital Health Wire, which flagged the gap, put it plainly: "not necessarily a down round, but the silence was deafening."
The product is a free, ad-supported clinical copilot that answers doctors' questions with citations to peer-reviewed literature, gated behind NPI verification so only clinicians get in. The company says more than two-thirds of US doctors use it, and Nadler has said US clinicians consulted the platform 42 million times in August alone. It has raised over $1 billion in the past year from Thrive Capital, DST, GV, Kleiner Perkins, Sequoia Capital and Nvidia, and it now plugs into Epic workflows at Memorial Sloan Kettering while integrating that hospital's OncoKB oncology database.
The pivot is the part worth watching: Nadler told Forbes that OpenEvidence plans to develop its own oncology therapies, with a first drug entering clinical trials before the end of the year and three more candidates next year, starting with rare cancers. He framed the move as going after "the stuff that they are not doing, and maybe can't do," using the company's reach into the clinic to find patients that large pharma cannot. A company with a distribution moat in front of most US physicians can plausibly become a drug developer; it can also end up fighting on two fronts while Abridge, Doximity, Wolters Kluwer and Elsevier push into the same workflow — and while OpenAI and Anthropic build healthcare tools of their own.
Business Insider adds that the round buys access to computing that could get scarcer if anti-AI sentiment curbs data-center expansion, and that OpenEvidence "could be open to selling itself" — a single-sourced line the same story hedges, noting it is unverified whether any acquirer is interested and that the company may prefer to stay independent.
What to watch: whether OpenEvidence ever formally announces this round, and whether that first trial starts by December.
The company most of American medicine consults quietly raised at a lower number than it floated — does that read as discipline, or as a warning? Tell us in the comments.
